Sepsis News and Research

Latest Sepsis News and Research

United Therapeutics submits pre-market approval application for use of Remodulin with implantable drug infusion system

United Therapeutics Corporation (NASDAQ: UTHR) announced today that Medtronic, Inc. (NYSE: MDT) has submitted a pre-market approval application to the U.S. Food and Drug Administration (FDA) for the use of Medtronic's SynchroMed® II implantable drug infusion system (including a newly developed catheter) for use with United Therapeutics' Remodulin® (treprostinil) Injection delivered intravenously to patients with pulmonary arterial hypertension.

25 Dec 2014

CytoSorbents starts trading on The Nasdaq Capital Market

CytoSorbents Corporation, a critical care immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber to reduce deadly inflammation in critically-ill and cardiac surgery patients, announced that it will commence trading today on The Nasdaq Capital Market under its current ticker symbol "CTSO".

23 Dec 2014

Lilly receives FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its third U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab).

16 Dec 2014

ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

Molecular Medicine, a peer-reviewed biomedical journal published by the Feinstein Institute Press, published the results of a new study reporting clinically significant pain reduction in type 2 diabetic patients. In an exploratory study conducted by Araim Pharmaceuticals, a biotech company developing novel treatments for chronic diseases, investigators also observed improvements in metabolic control in patients administered ARA 290.

16 Dec 2014

Lack of safe water, sanitation and hygiene kills mothers and newborns

WaterAid and the London School of Hygiene &Tropical Medicine today join the World Health Organization, UNICEF, UNFPA, SHARE Research Consortium and other organisations in a call to protect the lives of new mothers and their babies, by improving access to safe water, basic sanitation and hygiene in healthcare facilities and homes.

14 Dec 2014

Drug proves effective at inhibiting growth of drug-resistant bacteria

A treatment pioneered at the University of Pittsburgh Center for Vaccine Research is far more effective than traditional antibiotics at inhibiting the growth of drug-resistant bacteria, including so-called "superbugs" resistant to almost all existing antibiotics, which plague hospitals and nursing homes.

10 Dec 2014

Epizyme presents EPZ-5676 Phase 1 trial results for acute leukemia at ASH 2014

Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the presentation of results from the company’s Phase 1 trial of EPZ-5676, a potent and selective inhibitor of the DOT1L histone methyltransferase (HMT).

10 Dec 2014

Amgen announces new data from BLINCYTO Phase 2 study for treatment of patients with ALL

Amgen today announced that new data from a pivotal Phase 2 study evaluating BLINCYTO (blinatumomab) for the treatment of adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (ALL) was presented at the 56th American Society of Hematology Annual Meeting and Exposition.

9 Dec 2014

Combination therapy benefits patients with acute myeloid leukemia

Patients who relapse in their battle with acute myeloid leukemia (AML) may benefit from a phase three study of therapies that combine an existing agent, cytarabine, with a newer compound, vosaroxin.

8 Dec 2014

Novel targeted therapies and treatment combinations for leukemia

Recognizing that leukemia cannot be conquered with a "one-size-fits-all" approach, researchers are pursuing novel targeted therapies and combinations of existing treatment regimens with new agents for patient populations with historically poor prognoses, according to data presented today during the 56th American Society of Hematology Annual Meeting and Exposition.

7 Dec 2014

Researchers create synthetic surface to control adhesion of E. coli bacteria

A research team from Kiel University and Goethe University Frankfurt has jointly created a synthetic surface on which the adhesion of E. coli bacteria can be controlled. The layer, which is only approximately four nanometres thick, imitates the saccharide coating (glycocalyx) of cells onto which the bacteria adhere such as during an infection. This docking process can be switched on and off using light.

3 Dec 2014

Unique ability helps prolific bacterium to afflict humans, animals and even plants

New research has found that one of the world's most prolific bacteria manages to afflict humans, animals and even plants by way of a mechanism not before seen in any infectious microorganism -- a sense of touch. This unique ability helps make the bacteria Pseudomonas aeruginosa ubiquitous, but it also might leave these antibiotic-resistant organisms vulnerable to a new form of treatment.

23 Nov 2014

Great Basin Scientific seeks FDA approval for Group B Strep assay

Great Basin Scientific, Inc., a molecular diagnostics company, today announced it has submitted its Group B Strep assay to the U.S. Food and Drug Administration for 510(k) clearance.

19 Nov 2014

Experts focus on key issues impeding delivery of cardiac care in resource-limited settings

Critical care is defined by life-threatening conditions, which require close evaluation, monitoring, and treatment by appropriately trained health professionals. Cardiovascular care bears these same requirements.

14 Nov 2014

LSU Health New Orleans professor awarded $1.8 million grant to target intra-abdominal infections

Mairi Noverr, PhD, Associate Professor of Prosthodontics at LSU Health New Orleans School of Dentistry's Center of Excellence in Oral Biology, has been awarded a $1.8 million grant by the National Institute of Allergy and Infectious Diseases.

13 Nov 2014

New model explains how immune cells recognize, destroy bacteria

The innate immune system serves as the body's specialized armed forces division, comprised of a host of defense mechanisms used to battle bacterial infections. Among the system's warriors are white blood cells including the specialized macrophages, which maintain constant surveillance for foreign intruders or pathogens, functioning as the body's first line of defense, poised to attack at barrier sites including the skin, lungs and intestines.

11 Nov 2014

Inovio Pharmaceuticals reports Q3 2014 financial results, provides corporate update

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended September 30, 2014.

10 Nov 2014

Liposomes can help prevent bacterial toxins from killing human cells

Published in Nature Biotechnology, the study at the University of Liverpool showed that specially engineered lipid (fat) bodies, called liposomes, can be used to prevent bacterial toxins from killing human cells.

7 Nov 2014

Penn researchers show that 23% of patients who survive septic shock return to hospital within 30 days

A diagnosis of septic shock was once a near death sentence. At best, survivors suffered a substantially reduced quality of life.

6 Nov 2014

FDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma

Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for people with advanced or metastatic gastric (stomach) or gastroesophageal junction (GEJ) adenocarcinoma whose cancer has progressed on or after prior fluoropyrimidine- or platinum-containing chemotherapy.

5 Nov 2014